within Pharmacolibrary.Drugs.ATC.L;

model L01XX75
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.166666666666665e-07,
    adminDuration  = 600,
    adminMass      = 68 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00263,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00164,
    k12             = 0.128,
    k21             = 0.128
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX75</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tebentafusp is a bispecific fusion protein that targets glycoprotein 100 (gp100)-positive cells by redirecting T cells to recognize and destroy uveal melanoma cells. It is approved for the treatment of unresectable or metastatic uveal melanoma in adults.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with metastatic uveal melanoma; both sexes; typical clinical dosing regimen.</p><h4>References</h4><ol><li><p>Wang, Z, et al., &amp; Chen, Y (2023). Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. <i>Drugs of today (Barcelona, Spain : 1998)</i> 59(3) 179–193. DOI:<a href=\"https://doi.org/10.1358/dot.2023.59.3.3542417\">10.1358/dot.2023.59.3.3542417</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36847626/\">https://pubmed.ncbi.nlm.nih.gov/36847626</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX75;
